Developing novel photocatalytic cementitious permeable pavements for depollution of contaminants and impurities in urban cities

Photocatalyst such as Titanium Dioxide (TiO2) has been recently introduced as a nanoparticle into cementitious permeable pavements. Combining photocatalytic compounds within concrete permeable pavements can aid with depollution of several contaminants found in urban water streams and air impurities. This paper presents research carried out at the Uni-versity of Greenwich, UK using photocatalytic concrete with varying percentages of TiO2 (0 %, 1% and 5%) to assess the levels depollution which can be achieved.Concrete samples were testing against the degradation of 2, 4-Dichlorophenoxyacetic Acid, a harmful chemical found in herbicides. This advanced oxidation process can aid in the re-duction of urban pollution from an air and water perspective, improving sustainability for urban cities. Self-cleaning benefits of photocatalytic concrete permeable pavements can be used to keep urban infrastructure cleaner and more aesthetically pleasing. Experimental tests were carried out on the characterisation of inorganics through X-Ray diffraction and Fourier Transform Infrared Spectroscopy to ensure that the structures of the concrete samples were not altered by addition of the na-noparticles (photocatalyst). Experimental results were compared to that found in previous literature and confirmed that the addition of 5% TiO2 did not affect the structure of the concrete samples and can be a viable option used in urban infrastruc-ture such as permeable pavements

Efeito da adição de látex nas pastas de cimento branco no estado endurecido

Este trabalho investiga o impacto da utilização de látex poliméricos em propriedades de pastas de cimento Portland branco no estado endurecido. Para tanto, foram utilizados dois látex com propriedades físico-químicas distintas: EVA (etileno de vinil acetato) em pó redispersível, e SAE (estireno acrílico) na forma de emulsão. As pastas foram preparadas com relação água/cimento constante de 0,40, e as quantidades de látex foram variadas, de 5% a 20% de constituintes ativos em relação à massa de cimento. Apesar de os látex poliméricos terem afetado negativamente a reação de hidratação do cimento de forma distinta, houve aumento na resistência mecânica e redução da absorção de água e da permeabilidade ao vapor, com maior teor látex/cimento

Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.

Contains fulltext : 57737.pdf (publisher's version ) (Open Access)BACKGROUND AND OBJECTIVES: Acute myeloid leukemia (AML) in the elderly is associated with low rates of response to conventional chemotherapy and long-term survival, highlighting the need for innovative treatment strategies. Gemtuzumab ozogamicin (GO) is an immunoconjugate that has shown activity in relapsed AML with a favorable safety profile. The aim of this collaborative trial was to assess the feasibility, safety, and antileukemic activity of administering GO followed by conventional chemotherapy as first line therapy in patients aged 61-75 years with AML. DESIGN AND METHODS: Eligible patients received frontline treatment with GO 9 mg/m2 infused intravenously on days 1 and 15. Following response assessment to GO, patients were started on conventional chemotherapy consisting of the MICE regimen (mitoxantrone, cytarabine, etoposide). No further treatment was planned for complete responders. RESULTS: Among the 57 evaluable patients, 38 (67%) completed the entire sequential treatment as planned. The overall response rate to the entire induction sequence was 54.4% (31/57), with complete remission (CR) in 35.1% and complete remission with incomplete platelet recovery (CRp) in 19.3%. Rates of failure due to treatment-related mortality or resistant disease were 14.1% (3 toxic deaths during the GO segment, 5 during MICE) and 29.9%, respectively. An initial response to GO was documented in 20 patients (35.1%), with CR in 22.8% and CRp in 12.3%; 6 additional patients entered a partial remission. Reversible myelosuppression and liver toxicity were the main adverse events during both segments of induction. Frontline GO was associated with modest mucosal and gastrointestinal toxicity, but grade 3-4 pancytopenia was universal and prolonged. Hepatic veno-occlusive disease developed in 3 patients after GO and 2 after MICE, resulting in 4 deaths from liver failure. One-year survival at follow-up was 34%. Twelve patients continue in CR/CRp after a median of 226 days. INTERPRETATION AND CONCLUSIONS: The sequential combination of GO and conventional chemotherapy is a feasible and active treatment strategy for older patients with untreated AML. This novel regimen is now being compared in a phase III trial (AML-17)

Next generation concrete surface (NGCS) : finally a quiet and sustainable road pavement?

C